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Abstract
Background: Sepsis is the leading cause of death in Intensive Care Units. Novel sepsis biomarkers and targets for treatment
are needed to improve mortality from sepsis. MicroRNAs (miRNAs) have recently been used as finger prints for sepsis, and
our goal in this prospective study was to investigate if serum miRNAs identified in genome-wide scans could predict sepsis
mortality.
Methodology/Principal Findings: We enrolled 214 sepsis patients (117 survivors and 97 non-survivors based on 28-day
mortality). Solexa sequencing followed by quantitative reverse transcriptase polymerase chain reaction assays was used to
test for differences in the levels of miRNAs between survivors and non-survivors. miR-223, miR-15a, miR-16, miR-122, miR-
193*, and miR-483-5p were significantly differentially expressed. Receiver operating characteristic curves were generated
and the areas under the curve (AUC) for these six miRNAs for predicting sepsis mortality ranged from 0.610 (95%CI: 0.523–
0.697) to 0.790 (95%CI: 0.719–0.861). Logistic regression analysis showed that sepsis stage, Sequential Organ Failure
Assessment scores, Acute Physiology and Chronic Health Evaluation II scores, miR-15a, miR-16, miR-193b*, and miR-483-5p
were associated with death from sepsis. An analysis was done using these seven variables combined. The AUC for these
combined variables’ predictive probability was 0.953 (95% CI: 0.923–0.983), which was much higher than the AUCs for Acute
Physiology and Chronic Health Evaluation II scores (0.782; 95% CI: 0.712–0.851), Sequential Organ Failure Assessment scores
(0.752; 95% CI: 0.672–0.832), and procalcitonin levels (0.689; 95% CI: 0.611–0.784). With a cut-off point of 0.550, the
predictive value of the seven variables had a sensitivity of 88.5% and a specificity of 90.4%. Additionally, miR-193b* had the
highest odds ratio for sepsis mortality of 9.23 (95% CI: 1.20–71.16).
Conclusion/Significance: Six serum miRNA’s were identified as prognostic predictors for sepsis patients.
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Introduction
Sepsis is a state of sustained infection that results in a severe
systemic inflammatory response and, possibly, shock [1]. Despite
significant improvements in critical care medicine during recent
decades, sepsis remains as one of the leading causes of mortality in
the intensive care unit (ICU) [2]. Numerous studies have attempted
toidentifybiomarkerstopredictsepsismortality,includingserumC-
reactive protein (CRP), Procalcitonin (PCT) levels [3], and Acute
Physiology and Chronic Health Evaluation II scores (APACHE II)
and Sequential Organ Failure Assessment scores (SOFA) [4].
However, CRP levels on the day of sepsis diagnosis have
proved to have poor predictive value for mortality [5]. PCT,
APACHE II scores, and SOFA scores have shown better
predictive values compared to CRP levels; however, their areas
under receiver operating characteristic (AUROC) curves were
only 0.75 (95% CI: 0.66–0.85) [6], 0.75 (95% CI: 0.67–0.83),
and 0.8 (95% CI: 0.72–0.88), respectively [7]. Thus, the
sensitivities and specificities of these four biomarkers, which
are widely used in clinical practice, are not sufficiently high to
predict sepsis mortality.
MicroRNAs (miRNAs) are endogenous RNAs of ,22 nt that
play important regulatory roles by targeting mRNAs for cleavage
or translational repression [8]. Recently, serum or plasma
miRNAs levels have been shown to be stable and reproducible
[9,10], and the unique expression patterns of serum miRNAs can
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diseases [9,11]. To our knowledge, only miR-223 and miR-146a
have shown diagnostic value for sepsis and only one plasma
miRNA, miR-150, was identified as a potential biomarker for
sepsis prognosis [12]. As is well known, sepsis is a complex
syndrome that involves multiple organs and tissues, and not only
leukocytes, and a single biomarker is not sufficient to reflect the
severity of sepsis. Thus, a panel of biomarkers is needed to
evaluate sepsis prognosis.
There have been no studies that used genome-wide screening of
serum or plasma for sepsis prognosis or mortality from sepsis.
Numerous methods have been used to detect the genome-wide
expression profiles of miRNAs, such as Exqion miRCURY LNA
array technology, the Illumina BeadChip platform, the Febit
automated Geniom Real Time Analyzer platform, and Affymetrix
GeneChip miRNA array technology [13–15]. However, all of
these microarrays are limited due to the possibility of false positive
results. Next generation sequencing is now being used to detect
miRNA expression profiles in the sera of patients with different
diseases [16,17]. Compared to microarrays, these have shown
better detection capabilities both in terms of the quality and
quantity of miRNAs. These results showed that next generation
sequencing is a promising method for genome-wide miRNA
screening [18].
In this study, we first used Solexa sequencing to screen for
serum miRNAs among 9 surviving and 9 non-surviving sepsis
patients. Then, qRT-PCR was used to validate the Solexa
sequencing results in a cohort of 166 sepsis patients. After
validation, the predictive values of the screened miRNAs were
compared to those of currently used clinical biomarkers. A
multivariable logistic regression analysis was also used to evaluate
the predictive values and odds ratios of these miRNAs.
Results
Clinical Characterizations of the Sepsis Patients
From July 2010 to March 2011, a total of 214 sepsis patients
were screened. Based on 28-day mortality, they included 117
survivors and 97 non-survivors who were matched by sex
(p=0.406) and age (p=0.730). Pulmonary infection was the
leading cause of sepsis in these patients. There were no significant
differences in the causes of sepsis between the two groups
(pulmonary infection, p=0.179; post-surgery, p=0.591; acute
pancreatitis, p=0.981; multiple trauma, p=0.491). However,
APACHE II scores and SOFA scores were significantly different
between sepsis survivors and non-survivors (Table 1).
Genome-wide Screening for Serum miRNAs by Solexa
Sequencing
We selected 9 survivors and 9 non-survivors who were matched
by sex, age, and sepsis severity for initial Solexa sequencing
(Table 2). This sequencing detected 153 known miRNAs in the
non-surviving group and 173 known miRNAs in the surviving
group. The expression profiles of these miRNAs are shown in
Table S1 and Table S2. Then, we compared the expressions of
these known miRNA between the two groups; a large number of
miRNAs were differentially expressed (Table S3).
The level of an miRNA was considered to be significantly
differentially expressed only if two criteria were both satisfied: (1)
there were at least 20 copies in either the surviving or non-
surviving group [16]; and (2) there was at least a two-fold different
expression level between the two groups [16,19]. After screening,
11 miRNAs were identified. These included 6 up-regulated
miRNAs (miR-378, miR-483-5p, miR-193b*, miR-122, miR-
499-5p, miR-206) and 5 down-regulated miRNAs (miR-451, miR-
16, miR-15b, miR-15a, miR-486-5p) in the non-surviving group
compared to the surviving group; these are shown in Table 3.
Despite its low fold-change of 1.8, miR-223 was also chosen
because miR-223 had been previously proven to be a biomarker of
sepsis [20]. Thus, 12 miRNAs were selected for a small sample size
validation by qRT-PCR.
Table 1. Clinical data for 214 sepsis patients.
Variables
Survivors
(n=117)
Non-survivors
(n=97) P-value
Male/female 72/36 58/37 0.406
A
Ages (years) 60.7618.9 59.6618.8 0.730
B
Cause of sepsis (%)
Pulmonary infection 39(33.3%) 41(42.3%) 0.179
A
Post-surgery 30(25.6%) 23(23.7%) 0.591
A
Acute pancreatitis 10(8.5%) 7(7.2%) 0.981
A
Multiple trauma 17(14.6%) 11(11.3%) 0.491
A
Others 21(18.0%) 15(15.5%) 0.629
A
Intercurrent conditions
CHD
# 15(12.8%) 10(10.3%) 0.569
A
Cancer 9(7.7%) 13(13.4%) 0.171
A
Hypertension 21(17.9%) 17(17.5) 0.936
A
Diabetes 7(6.0%) 5(5.2%) 0.793
A
COPD* 25(21.4%) 20(17.1%) 0.894
A
SOFA score 5.8063.33 9.5463.33 ,0.001
B
APACHE II score 15.7566.46 22.7266.62 ,0.001
B
CRP (mg/dl) 3.5(0.2,6.2) 12.15(6.7,32.8) 0.687
C
PCT (ng/ml) 1.97(0.05,3.78) 8.29(3.91,191.44) ,0.001
C
A: Chi Square tests; B: Student t test; C: Mann-Whitney U tests; #: Coronary
heart disease;
*: Chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0038885.t001
Table 2. Clinical characteristics of the sepsis patients used for
Solexa sequencing.
Variables
Survivors
(n=9)
Non-survivors
(n=9) p-value
Male/female 6/3 7/2 0.599
A
Ages (years) 62.3620.8 60.9621.5 0.887
B
Type
Sepsis 3 3 -
Severe sepsis 3 3 -
Septic shock 3 3 -
SOFA scores 6.063.7 9.663.6 0.057
B
APACHE II 14.566.5 20.966.0 0.060
B
CRP (mg/dl) 13.8 (6.1, 20.6) 14.15 (0.5, 22.2) 0.116
B
PCT (ng/ml) 4.87(0.37,10.36) 10.18(0.45,32.76) 0.404
B
WBC (610
9/L) 11.84(3.01,23.29) 10.08(7.62,29.6) 0.559
B
A: Chi Square tests; B: Mann-Whitney U tests.
doi:10.1371/journal.pone.0038885.t002
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24 healthy controls were used to normalize the expression levels
of the miRNAs measured in our study and all of these miRNAs
were detectable in normal controls’ sera. Based on previous results
[21,22], U6 snRNA was selected as an internal normalization
control for miRNA qPCR. In our study, there were no significant
differences in raw Ct values for U6 snRNA among normal
controls, non-survivors, and survivors (p=0.376; Kruskal-Wallis
H).
We used qRT-PCR to validate the altered expressions of the 12
candidate miRNAs for 15 survivors and 15 non-survivors. After
validation, seven miRNAs were identified (associated p-values in
parentheses): miR-223 (p=0.015); miR-15a (p=0.005); miR-16
(p=0.021); miR-499-5p (p=0.006); miR-122 (p,0.001), miR-
193b*(p,0.001) and miR-483-5p (p,0.001). Compared to the
surviving group, miR-16 and miR-223 were up-regulated in the
non-surviving group and the levels of miR-15a, miR-499-5p, miR-
193b*, miR-122, and miR-483-5p were up-regulated (Figure 1).
Although levels of miR-15b were not significantly different in the
validation set, previous study has proved that levels of miR-15b
were significantly higher than other expressed miRNAs in T cell
subsets [23]. Hence, miR-15b was also selected for further
confirmation.
Next, the eight differentially expressed miRNAs were further
validated in a confirmation set comprised of 93 survivors and 73
non-survivors. As a result, two of the eight miRNAs’ levels (miR-
15b and miR-499-5p) were not significantly different. Six miRNAs
were confirmed to be significantly differentially expressed and
these miRNA expression pattern alterations in the confirmation set
were consistent with those of the validation set. The expression
levels of miR-15a (p=0.015), miR-193b* (p,0.001), miR-122
(p,0.001), and miR-483-5p (p,0.001) in non-survivors were
significantly higher than in survivors, and the levels of miR-
223(p,0.001) and miR-16 (p,0.001) were significantly lower
(Figure 2).
Comparisons of the Predictive Mortality Values of the Six
miRNAs with SOFA Scores, APACHE II Scores, and PCT
Levels
To investigate the predictive mortality value of the six
confirmed miRNAs, receiver operating characteristic (ROC)
curves were generated and the areas under the curves (AUCs)
were calculated. The AUCs for the six miRNAs ranged from
0.610 (95%CI: 0.523–0.697) to 0.790 (95%CI: 0.719–0.861)
(Figure 3). The AUCs for SOFA scores, APACHE II scores,
and PCT levels were, respectively, 0.782 (95%CI: 0.712–0.851),
0.752 (95%CI: 0.672–0.832), and 0.689 (95%CI: 0.611–0.784)
(Figure 4). The AUC for miR-193b* had the highest value,
followed by those for SOFA scores and miR-16. AUCs for miR-
223 and miR-122 were nearly identical to the AUC for APACHE
II scores.
Four Serum miRNAs Identified as Risk Factors for Sepsis
Patients’ Prognosis
Logistic regression analysis was used to evaluate possible
associations between the six miRNAs and sepsis patients’
mortality. First, univariate logistic regression was used for the six
miRNAs along with sepsis stage (sepsis=1, severe sepsis=2, septic
shock=3), age, sex, SOFA scores, APACHE II scores, CRP and
PCT levels, white blood cell counts (WBC), coronary heart
diseases (CHD), diabetes, hypotension, and COPD. The sepsis
stage, six serum miRNAs, SOFA scores, APACHE II scores, PCT
levels and diabetes were significantly different between survivors
and non-survivors (all p,0.05). These variables were used in
multivariable logistic regression analysis.
Only the sepsis stage, SOFA scores, APACHE II scores, miR-
15a, miR-16, miR193b*, and miR-483-5p were entered into the
final regression equation (Table 4). The predictive values of these
seven variables were evaluated by ROC analysis. The AUC of
these combined seven variables was 0.953 (95%CI: 0.923–0.985),
which was much higher than SOFA scores, APACHE II scores, or
any of the miRNAs (Figure 4). When the cut-off point was set at
0.550, the predictive value of the seven variables had a sensitivity
of 88.5% and a specificity of 90.4%. Then, we calculated the
predictive value when only SOFA and APACHE II scores were
combined. The AUC was 0.891 (95%CI: 0.843–0.939), which was
lower than when the miRNAs results were added.
Among these seven factors, miR-193b* had the highest odds
ratio (OR) of 9.07 (95% CI: 1.32–62.42), followed by sepsis stage,
miR-483-5p, SOFA scores, APACHE II scores, miR-15a, and
miR-16 with ORs, respectively, of 6.96 (95% CI: 2.11–22.99),
1.29 (95% CI: 1.08–1.55), 1.25 (95%CI: 1.01, 1.54), 1.14 (95% CI:
1.02–1.27), 1.03 (95% CI: 1.00–1.07), and 0.60 (95% CI: 0.45–
0.81). These results indicated that sepsis stage, miR-193b*, miR-
483-5p, APACHE II scores, and miR-15a were independent risk
factors for sepsis patients’ death. miR-16 was identified as a factor
associated with decreased risk of death for sepsis patients.
Discussion
Several circulating miRNAs have recently been reported to be
biomarkers for sepsis diagnosis and prognosis [12,20]. In our
study, a genome-wide Solexa method was first used to screen 18
sepsis patients’ sera for miRNAs. Then, qRT-PCR was used for
196 sepsis patients to confirm the results of Solexa sequencing.
Two methods for validation and a large sample size made our
results more convincing. As a result, six miRNAs were confirmed
to be significantly differentially expressed between sepsis survivors
and non-survivors.
Table 3. Fold-changes of selected miRNAs in Non-survivors
(D) and Survivors (S).
miR-names Fold-change* p-value
Down-regulated in
non-survivors’ sera
hsa-miR-451 –3.27 0
hsa-miR-16 –3.21 0
hsa-miR-15b –3.07 0
hsa-miR-15a –2.28 ,0.001
hsa-miR-486-5p –2.19 0
hsa-miR-223 –1.81 ,0.001
Up-regulated in
non-survivors’ sera
hsa-miR-378 2.38 ,0.001
hsa-miR-483-5p 2.05 0
hsa-miR-193b* 2.77 0
hsa-miR-122 3.14 0
hsa-miR-499-5p 4.40 0
hsa-miR-206 4.88 0
*Fold change formula: Fold-change=log2 (D/S).
doi:10.1371/journal.pone.0038885.t003
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for sepsis mortality was better than SOFA scores and APACHE II
scores, which are both composites that integrate numerous sepsis
indicators. However, serum miR-15a and miR-483-5p had poor
predictive values for sepsis mortality. Thus, we used a logistic
regression analysis to select those miRNAs that were associated
with death from sepsis. These results showed that a combination of
miR-15a, miR-16, miR-193b*, miR-483-5p, SOFA scores,
APACHE II scores, and sepsis stage had a much better predictive
value for mortality. Therefore, if we were to integrate these six
miRNAs into a composite indicator in clinical practice, this
composite indicator would have a much better predictive value for
sepsis mortality than SOFA scores and APACHE II scores.
These six miRNAs were differentially expressed even when
survivors and non-survivors were matched by sepsis severity.
Hence, these biomarkers may be genetic markers and may not
necessarily be suitable for characterizing sepsis progression.
Functional studies involving these biomarkers will be needed,
which may provide additional valuable information for treating
physicians.
Previous studies of miRNAs in sepsis patients primarily
focused on the miRNA expression profiles of WBCs. miR-146b,
miR-150, miR-342, and miR-let-7 g were found to be
differentially expressed by WBCs from healthy donors after
treatment with E. Coli lipopolysaccharide (LPS) infusion for 4
hours [24], and miR-150, miR-182, miR-342-5p, and miR-486
were identified in WBCs from sepsis patients’ peripheral blood
[12]. However, none of these miRNAs were present in the
expression profiles of our six miRNAs. These differences may be
due to the following reasons.
In peripheral blood serum, circulating miRNAs are found in
microvesicles (MVs), which have been identified as carriers of
genetic information exchange between cells [25]. The majority of
peripheral blood MVs derive from platelets [26,27] and a second,
large population of MVs derives from mononuclear phagocyte cell
lineages. Only a small percentage of MVs are derived from T-cells
and neutrophils [27]. In sepsis patients, WBCs are not the only
blood cells that are involved in sepsis pathogenesis. Thus, the
serum miRNAs screened for using a genome-wide method might
derive mostly from other sources given the small percentage of
miRNAs from white cells.
Functional studies of these screened miRNAs in our study
have already been performed by other investigators. miR-223,
miR-15a, and miR-16 have been found to be associated with
the innate immune system by targeting IKKa mRNA, which is
involved in the NF-kB signaling pathway [28]. Functional
studies of miR-193b* have mostly focused on cancer [29,30].
miR-122, a liver-specific miRNA, was found to be associated
with hepatocellular carcinoma [31] and chronic hepatitis [32].
Abnormal expression of miR-483-5p was indicative of a poor
Figure 1. Comparison of 12 miRNAs expression levels between sepsis non-survivors and survivors in a validation set. Differentially
expressed miRNAs identified by Solexa sequencing were validated by qRT-PCR in sepsis survivors (S; N=15) compared to non-survivors (D; N=15).
MiR-16 (p=0.005), miR-15a (p=0.021), miR-223 (p=0.015), miR-483-5p (p,0.001), miR-193b* (p,0.001), miR-122 (p,0.001), and miR-499-5p (p=0.006)
were significantly different after validation with qRT-PCR. Expression levels of the 12 miRNAs were normalized to U6 snRNA above normal controls
and given as fold-changes (2
–DDCt ). ggCt = (CtmiRNA-CtU6 snRNA) patients-(CtmiRNA-CtU6 snRNA)controls. Mann-Whitney U-test was used for statistical
comparisons.
doi:10.1371/journal.pone.0038885.g001
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functional study has shown that these miRNAs were associated
with sepsis. Hence, much work needs to be done.
This study was novel in several respects. First, we addressed a
significant medical condition-sepsis-from a new perspective: the
involvement of serum miRNAs. Second, Solexa sequencing was
first used for genome-wide screening of sepsis patients’ sera to
identify differentially expressed miRNAs. Third, this was the first
time that a high- throughput method was used to screen for serum
miRNAs to evaluate sepsis prognosis. Finally, this is the first report
to show that miR-16, miR-15a, miR-193b*, and miR-483-5p were
associated with sepsis prognosis.
However, this study had some limitations. We only used 9
survivors and 9 non-survivors in our discovery set. Although six
miRNAs were found to be valuable for predicting mortality of
sepsis patients, a number of miRNAs with low expression levels
might have been left out during the initial screening by Solexa
sequencing. The 9 samples in each group were comprised of 3
sepsis patients, 3 severe sepsis patients, and 3 septic shock patients.
Solexa sequencing performed only for single subgroups may
discover some specific miRNAs in these subgroups. Another
limitation was that miR-499 were significantly differentially
expressed in the validation set with p value of 0.006 but not in
confirmation set with value of 0.196. This result meant that
relatively small numbers in sample groups could readily give
misleading results and these results of our study were still needed
to be validated in a much larger sample group. In addition,
conditions of the patients and comorbidity influences may also
affect the results. In addition, in our study, we only evaluated the
levels of these miRNAs in patients who were admitted to ICU
within 24 hours. Whether there is a progression or increase of
these biomarkers when these patients approach death is still
unknown. Hence, evaluation of the dynamic changes of these
miRNAs during the sepsis process was essential to our further
study.
Regardless of these limitations, the six miRNAs were found to
be valuable predictors of sepsis mortality. In future studies, a focus
on the trends of the expression level changes of these six miRNAs
during hospitalization in the ICU would be even more valuable. In
addition, predicting the target genes of these six miRNAs and post-
experimental validation of these target genes may provide new
targets for the treatment of sepsis.
In conclusion, six serum miRNAs identified in our study can be
used to predict sepsis patients’ mortality.
Figure 2. Expression levels of 8 miRNAs in sepsis non-survivors and survivors in a confirmation set. These 8 miRNAs were significantly
differentially expressed between sepsis non-survivors and survivors after qRT-PCR validation in a smaller study sample. Then, these were checked by
qRT-PCR in a larger study sample size (Non-survivors=D, n=73; Survivors=S, n=93). Only 6 of the 8 miRNAs remained as significantly different
between the D group and S groups. Expression levels of these 8 miRNAs were normalized to U6 snRNA U6 snRNA above normal controls and given as
fold-changes (2
–DDCt ), ggCt= (CtmiRNA-CtU6 snRNA)patients-(CtmiRNA-CtU6 snRNA)controls. Mann-Whitney U-test or student t-test was used for statistical
comparisons.
doi:10.1371/journal.pone.0038885.g002
Figure 3. Receiver operating characteristic (ROC) curves for serum miRNAs for sepsis non-survivors (n=73) and survivors (n=93).
These six miRNAs were finally confirmed by qRT-PCR. Areas under the ROC curves are also shown.
doi:10.1371/journal.pone.0038885.g003
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The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
Written informed consent was obtained from all sepsis patients
and normal controls. This study was approved by the Committee
on Ethics of the Chinese PLA General Hospital.
Study Subjects
All patients who were diagnosed with sepsis met the definitions
of the American College of Chest Physicians/Society of Critical
Care Medicine (ACCP/SCCM) [34]. Patients younger than 18
years of age or those who were immunosuppressed were
excluded from this study. Patients who did not receive adequate
treatment because of economic hardship were also excluded. A
total of 214 sepsis patients (117 survivors and 97 non-survivors)
were enrolled from July 2010 to March 2011. Healthy controls
(n=24) were recruited from the Health Screening Center of the
Chinese PLA General Hospital and they did not have any type
of known infection or known medical condition.
Based on 28-day mortality, we divided sepsis patients into a
surviving group and a non-surviving group. First, to detect
differently expressed miRNAs between the surviving and non-
surviving groups, 9 survivors and 9 non-survivors who were
matched by sex (p=0.902), age (p=0.887), and sepsis severity
(SOFA scores, p=0.057; APACHE II scores, p=0.060) were
screened by Solexa sequencing (miRBase 15.0). Next, qRT-PCR
was used in a validation set (15 survivors and 15 non-survivors)
who were also matched by sex (p=0.821), age (p=0.329), and
sepsis severity (SOFA scores, p=0.089; APACHE II scores,
p=0.071) to validate the Solexa sequencing results in a small
sample size. Finally, the validated serum miRNAs in the small
sample size were confirmed in a confirmation set (93 survivors and
73 non-survivors).
Blood Samples and Serum Total RNA Isolation
Blood samples of all the patients were drawn within 24 hours
after a diagnosis of sepsis was made. Coagulated blood samples
were collected in tubes containing a separating gel and clot
activator and centrifuged at 3000 rpm for 15 min at room
temperature. The supernatant was transferred to Eppendorf
tubes. These samples were centrifuged at 15,000 rpm for
30 min to precipitate cell debris, and the supernatants were
Figure 4. Receiver operating characteristic (ROC) curves for serum miRNAs and clinically used indicators for sepsis non-survivors
(n=73) and survivors (n=93). Serum levels of miRNAs were quantified using real time qPCR. Each qPCR was done in triplicate in 96-well plates.
Expression levels of the selected miRNAs were normalized to U6 snRNA and presented as fold-changes (2
-DDCt) above normal controls.
doi:10.1371/journal.pone.0038885.g004
Serum miRNAs Predict Sepsis Mortality
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38885stored at -80uC until RNA extraction. Serum total RNA was
isolated using a mirVana PARIS kit (Ambion, #1556)
according to the manufacturer ‘s instructions. All serum RNA
preparations were pre-treated with RNase-free DNase I
(Promega) to eliminate potential DNA contamination.
Solexa Sequencing and Bioinformatics Analysis
The serum samples of 9 survivors and 9 non-survivors were
pooled for their respective groups. Total RNA was purified
directly for Solexa sequencing analysis using an Illumina Genome
Analyzer (Illumina, San Diego, CA, USA) according to the
manufacturer’s instructions [35]. Briefly, a pair of Solexa adaptors
were ligated to the 5’ and 3’ ends of total RNA, and small RNA
molecules were amplified by reverse transcription PCR (RT-PCR)
using a RT-PCR kit (Invitrogen). The adaptor primers for 17
cycles and fragments around 30 bp (small RNA + adaptors) were
isolated from an agarose gel. Purified RNA was used directly for
cluster generation and sequencing analysis using an Illumina
Genome Analyzer (Illumina, San Diego, CA, USA) according to
the manufacturer’s instructions. After a bioinformatics analysis
[36], the remaining miRNAs were searched against the Sanger
miRBase (version15.0) [37] to identify conserved, known miRNAs.
Then, the fold-changes of the known miRNAs between the two
groups were determined by: Log2(copies of non-survivors/copies
of survivors). This work was done at the Beijing Genomics Institute
(BGI).
qRT-PCR Validation
After total RNA isolation, reverse transcription (RT) was done
in a reaction volume of 7.5 mL, which contained 2.08 mL of water,
0.75 mLo f1 0 6 reverse transcription buffer, 0.095 mL of RNase
inhibitor, 0.075 mL of dNTPs, 0.5 mL of Multiscribe reverse
transcriptase, 1.5 mL of miRNA-specific stem-loop RT primer
(Applied Biosystems), and 2.5 mL (5 ng) of digested RNA
preparations. RT used a Mastercycler Ep Gradient at 16uC for
30 min, 42uC for 30 min, and 85uC for 5 min. Real-time qPCR
used a TaqMan MicroRNA assay (Applied Biosystems). Briefly,
4.5 mL of 5:28 diluted RT product was combined with 5.0 mLo f
TaqMan gene expression Master Mix and 0.5 mL of Taqman
miRNA assay. qPCR used an ABI PRISM 7300 detection system
at 95uC for 5 min, followed by 40 cycles of 95uC for 15 s and
60uC for 1 min. All qPCR reactions were performed in triplicate
and the raw Ct (threshold cycle) of each sample was the mean
value of three Ct values. The data were analyzed by the 2
-DDCT
method.
CRP and PCT Determinations
Serum CRP levels were determined using scattering turbidim-
etry (CardioPhase hsCRP, Siemens, Germany) and PCT was
determined using an enzyme-linked fluorescence analysis kit
(ELFA, VIDAS BRAHMS PCT kit, bioMerieux SA, France).
All assays were done according to the manufacturer’s instructions
and duplicate measurements were made.
Statistical Methods
Expression levels of selected miRNAs detected by qRT-PCR
were normalized to U6 snRNA and presented as the fold-
change (2
-DDCt) above the normal control: ggCt = (CtmiRNA-
CtU6 snRNA)patients-(CtmiRNA-CtU6 snRNA)controls. Results for nor-
mally distributed continuous variables are given as means
(6standard errors of the mean) and compared between groups
by Student’s t-tests. Results for non-normally distributed
continuous variables are summarized as medians (interquartile
ranges) and were compared by Mann-Whitney U tests. To
evaluate the predictive values of selected miRNAs, ROC curves
were generated and the areas under the curves were
determined. Multivariable logistic regression analysis was used
to screen for independent risk or protective factors for sepsis.
Then, an analysis of a combination of these screened variables
was done and areas under the curve for the predictive
probabilities of these variables were also determined. P-values
,0.05 were considered statistically significant. All statistical
analyses used SPSS software (version 16.0).
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
Table S1 Expression profiles of serum miRNAs in non-
surviving sepsis patients (n=9) detected by Solexa
sequencing.
(DOC)
Table S2 Expression profiles of serum miRNAs in
surviving sepsis patients (n=9) detected by Solexa
sequencing.
(DOC)
Table S3 Comparisons of miRNAs between 9 survivors
(S) and 9 non-survivors (D) detected by Solexa sequenc-
ing.
(XLS)
Table 4. Multivariate logistic regression analysis of the
variables (Forward conditional).
Variables Univariate Multivariate
ORs p-value ORs p-value
Sepsis stage 3.15(1.94, 5.10) ,0.001 6.96(2.11,22.99) 0.001
Sex 1.51(0.78, 2.92) 0.23 - -
Ages 0.99(0.98, 1.00) 0.73 - -
SOFA score 1.37(1.23, 1.53) ,0.001 1.25(1.01, 1.54) 0.039
APACHE II 1.18(1.10, 1.26) ,0.001 1.14(1.02,1.27) 0.026
CRP 1.02(0.98, 1.07) 0.33 - -
PCT 1.06(1.03, 1.10) 0.001 - -
WBC 1.01(0.96, 1.06) 0.817 - -
Serum miR-223 0.67(0.54, 0.82) ,0.001 - -
Serum miR-15a 1.02(1.00, 1.04) 0.022 1.03(1.00, 1.07) 0.037
Serum miR-16 0.81(0.72, 0.91) ,0.001 0.60(0.45,0.81) 0.001
Serum miR-122 5.23(2.40,11.41) 0.02 - -
Serum miR-193b* 37.88(10.64,134.90) ,0.001 9.07(1.32,62.42) 0.025
Serum miR-483-5p 1.08(1.01, 1.15) 0.007 1.29(1.08,1.55) 0.006
CHD 1.31(0.55, 3.11) 0.548 _ _
Diabetes 3.74(1.14, 12.31) 0.030 _ _
Hypotension 1,70(0.70, 4.14) 0.245 _ _
COPD 1.37(0.52, 3.58) 0.525 _ _
doi:10.1371/journal.pone.0038885.t004
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